Journal of the Dermatology Nurses' Association

April 2009, Volume 1 Number 2 , p 147 - 148 [FREE]


  • William Abramovits MD
  • Debra L. Breneman MD
  • Alan B. Fleischer MD
  • Joshua Zeichner MD
  • Toni Shull RN, CCRC


function set_JnlFullText_Print() { metaTag = document.createElement('meta'); metaTag.setAttribute('name','OvidPageId'); metaTag.setAttribute('content','JnlFullText_Print'); head = document.getElementsByTagName('head')[0]; head.appendChild(metaTag); return; } if (window.addEventListener) { // DOM Level 2 Event Module (NS 6+) // Firefox throws an uncaught exception error executing this // code, even though it seems to work. Adding a do nothing // try/catch clause around it for now, since the exection itself // appears to be innocuous try { window.addEventListener('onload',set_JnlFullText_Print(),false); } catch(e) {} } else if (window.attachEvent) { // IE 5+ Event Model window.attachEvent('onload',set_JnlFullText_Print); } // For anything else, just don't add the event Print Close Journal of the Dermatology Nurses' Association Utility in Flare Prevention and Maintenance Therapy of Long-Term Intermittent Treatment With Tacrolimus Ointment in Patients With Atopic Dermatitis DOI: 10.1097/01.JDN.0000350430.08369.7b ...



Atopic dermatitis (AD) is characterized by disease-free periods interrupted by exacerbations (C. A. Akdis, 2006). Maintenance therapy with tacrolimus ointment may prevent disease recurrence.



Pediatric and adult patients with clear or almost clear disease after <=16 weeks of treatment with tacrolimus ointment were randomized to receive either vehicle or tacrolimus ointment (pediatric = 0.03%; adult = 0.1%) in the maintenance phase of this study. The safety and efficacy of tacrolimus therapy for recurrence prevention were evaluated (D. Breneman, 2008).



A total of 197 of 288 patients with clear or almost clear disease were eligible and entered the maintenance phase of this study. Patients treated with tacrolimus ointment had more flare-free treatment days than those treated with vehicle (M = 177.4 vs. 134.1; p = .003), a longer time to first relapse (median = 169 vs. 43; p = .037), fewer relapse days (45.5 vs. 64.5; p = .027) and fewer relapses per patient (p = .027). The severity of relapses was similar for both groups (p = .140) as was the incidence of cutaneous adverse events (tacrolimus ointment = 8.0%; vehicle = 8.5%). The most common adverse events were application-site burning and pruritus (D. Breneman, 2008).



Long-term treatment with tacrolimus ointment in patients with clear or almost clear AD results in significantly more disease-free days and safely and effectively reduces the risk for disease relapse.



When used as directed, treatment with tacrolimus ointment is a safe and effective method to control disease in patients with stabilized AD.



Akdis, C. A., Akdis, M., Bieber, T., Bindslev-Jensen, C., Boguniewicz, M., Eigenmann, P., et al. (2006). Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy, 61, 969-987. [Context Link]


Breneman, D., Fleischer, A. B. Jr., Abramovits, W., Zeichner, J., Gold, M. H., Kirsner, R. S., et al. (2008). Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. Journal of the American Academy of Dermatology, 58, 990-999. [Context Link]